Skip to main content
. Author manuscript; available in PMC: 2023 Apr 21.
Published in final edited form as: Science. 2021 Sep 16;373(6561):eabi8835. doi: 10.1126/science.abi8835

Figure 1. Enhanced mucosal type 1 responses and intact mucosal type 17 responses in APECED patients are evident across all age groups and regardless of the presence of Sjögren’s syndrome.

Figure 1.

(A) Concentrations of IL-17- and IL-22-dependent S100A8 and S100A9 in saliva of healthy volunteers (HV) (n=33) and APECED patients of the indicated age groups (n=11, 30, 12, 13, and 8 for 0-10, 10-20, 20-30, 30-40, and >40-year-old APECED patients, respectively). (B) Concentrations of IL-17- and IL-22-dependent S100A8 and S100A9 in saliva of HV (n=33) and APECED patients with (n=25) or without Sjögren’s syndrome (n=49). (C) Concentrations of IFN-γ-inducible CXCL9 and CXCL10 in saliva of HV (n=28-31) and APECED patients of the indicated age groups (n=12, 30-32, 10-12, 13-14, and 8-9 for 0-10, 10-20, 20-30, 30-40, and >40-year-old APECED patients, respectively). (D) Concentrations of IFN-γ-inducible CXCL9 and CXCL10 in saliva of HV (n=28-31) and APECED patients with (n=23-28) or without Sjögren’s syndrome (n=50-51). Data are excerpted from Figures 2D, 5E, and 5F of Break et al (1). All quantitative data are means ± SEM. ns, not significant, *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 as calculated using Kruskal–Wallis H test with Dunn’s multiple-comparisons test.